BIOTECHNOLOGY company
CSL has posted net profit after tax
for the year to June of US$1.31b
(A$1.41b), up 7.8% from the
previous year.
CSL said about 10% of its
revenues were generated in
Australia.
The company reported sales
revenue of US$5.3b, up 7.7% from
the previous year’s US$4.95b.
bioCSL sales declined 4% to
$433m with strong demand in the
US more than offset by a reduction
in European sales due to a market
exit by the company’s business
partner, it said.
However sales of vaccines for
measles, mumps and rubella grew
strongly after successfully tendering
for the Australian National
Immunisation Program, CSL said.
Two executive key management
personnel were based in Australia
with the remaining six now based
outside the country, CSL said.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Aug 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.